Amicus Therapeutics Treatments for Rare Disease
Amicus Therapeutics is a fifteen-year-old biopharmaceutical company specializing in rare and orphan diseases. Because of Amicus Therapeutics work with rare diseases they have received grants from The Michael J Fox Foundation & Alzheimer’s Drug Discovery Foundation. The public company’s focus at the moment is on a therapy for genetic diagnosis of Fabry disease. Fabry disease is rare and often misdiagnosed and is often found by symptoms of pain, kidney failure and cardiac complications. Amicus Therapeutics is also under development for a rare genetic connective tissue disorder called Epidermolysis Bullosa. This treatment named SD-101, at present, would be a first to market treatment for EB which can cause painful blisters and skin fragility.
Amicus Therapeutics and other innovative pharmaceutical companies like this will lead health care in the next decades. With more technology and understanding of disease and the body, there will be more opportunity for companies like Amicus Therapeutics to focus on unique market positions to be able to reach many Americans that are not being treated currently. Pain inducing diseases like Fabry disease are becoming more diagnosed as doctors begin to take pain seriously and look further than just pain management into the treatment of the causes of the pain. In 2008 the company expanded from a single New Jersey office, adding an office in San Diego as well. View the market summary of Amicus Therapeutics at finance.google.com.
Amicus Therapeutics expects further growth with the 2015 acquisition of Scioderm. The company’s commitment to innovation, smart risks, and the families and people that have these rare diseases will mean success for the company and the people that are counting Amicus Therapeutics to improve their everyday life. They are committed to being at the forefront of innovation in the development and research into therapies for rare diseases that often go unnoticed and under treated. They are dedicated to patients and families, and improving lives. Read the company profile at Crunchbase.